Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)

Abiraterone acetate plus prednisone is a standard treatment option for mCRPC. The phase II SWITCH trial showed that further prostate-specific antigen (PSA) responses can be obtained in a subset of patients when prednisone was switched to dexamethasone at progression. Here, we discuss the potential u...

Descripción completa

Detalles Bibliográficos
Autores principales: Teo, Min Yuen, Scher, Howard I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219496/
https://www.ncbi.nlm.nih.gov/pubmed/30344307
http://dx.doi.org/10.1038/s41416-018-0239-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219496/
https://www.ncbi.nlm.nih.gov/pubmed/30344307
http://dx.doi.org/10.1038/s41416-018-0239-y

Ejemplares similares